Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)
Launched by PEKING UNIVERSITY THIRD HOSPITAL · May 2, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the complex reasons behind low back pain, which can be either short-term (acute) or long-term (chronic). Researchers want to understand how factors like genetics, emotions, sleep, and other health conditions affect pain. They will collect samples and data from participants to help identify different types of low back pain and their underlying causes. The ultimate goal is to develop better ways to predict how pain progresses and to create personalized treatments that work for different individuals.
To participate, you need to be an adult aged 18 to 80 who has been diagnosed with low back pain. You should be open to various treatment options and willing to undergo some tests, like brain scans and psychological assessments. However, those with severe neurological issues, certain digestive diseases, or who have had specific recent medical treatments may not qualify. Participants can expect to contribute to important research that could lead to better pain management strategies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults aged 18 to 80 years.
- • 2. Diagnosis of low back pain, defined as pain located between the lower costal margins and the gluteal folds, with or without leg pain.
- • 3. Eligible for surgical or non-surgical treatments.
- • 4. Willingness to undergo neuroimaging (fMRI), microbiota sampling, psychological assessments, and other related study procedures. Ability to provide written informed consent.
- Exclusion Criteria:
- • 1. Severe neurological deficits requiring emergency surgery.
- • 2. Antibiotic or probiotic use within the past 4 weeks. Suffering from digestive diseases such as irritable bowel syndrome, gastric ulcer, duodenal ulcer, etc.;
- • 3. Diagnosed spinal infections, tumors, fractures, or inflammatory diseases (e.g., ankylosing spondylitis).
- • 4. Known severe psychiatric disorders (e.g., schizophrenia, bipolar disorder) that would interfere with study participation.Head trauma; history of substance abuse.
- • 5. Contraindications to MRI scanning (e.g., pacemaker, metallic implants, severe claustrophobia).
- • 6. Pregnant or breastfeeding women.
- • 7. Participation in another interventional clinical trial within the past 3 months.
- • 8. Working at night shifts or travelling across time zones in the past 6 months.
- • 9. Excessive consumption of coffee, tea.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jie Sun
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported